Erbitux lands another indication

Merck KGaA's (MKGAF) Erbitux gets an additional indication from the European Commission.

The drug is now approved for the treatment of RAS wild-type metastatic colorectal cancer.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs